Pharvaris publishes AAE-C1INH disease burden study in Frontiers in Immunology
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology
August 6, 2026 6:50 AM EDTPeople with AAE-C1INH experience frequent misdiagnoses, emergency medical events, and wide-ranging impact on physical, emotional, and social well-beingStudy results informed the design and endpoint selection of the ongoing Phase 3 CREAATE study
ZUG, Switzerland, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as... More
